Advanced Lung Carcinoma Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting advanced lung carcinoma clinical trials across 5 countries. Studies span Phase 2, Phase 1. Top locations include Melbourne, Victoria, Australia, New Haven, Connecticut, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Advanced Lung Carcinoma Trials at a Glance

7 actively recruiting trials for advanced lung carcinoma are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Melbourne, New Haven, and Houston. Lead sponsors running advanced lung carcinoma studies include Mayo Clinic, TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), and Jun Zhang, MD, PhD.

Browse advanced lung carcinoma trials by phase

Treatments under study

About Advanced Lung Carcinoma Clinical Trials

Looking for clinical trials for Advanced Lung Carcinoma? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Lung Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Lung Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Non-small Cell Lung CancerNSCLCMetastatic Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)665 enrolled17 locationsNCT06917079
Recruiting
Phase 1

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Non-small Cell Lung CancerMetastatic Lung CancerNSCLC+3 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)350 enrolled35 locationsNCT06343402
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Locally Advanced Hepatocellular CarcinomaLocally Advanced Gastric CarcinomaAdvanced Biliary Tract Carcinoma+7 more
OHSU Knight Cancer Institute66 enrolled1 locationNCT05705492
Recruiting

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Malignant Solid Neoplasm+7 more
Mayo Clinic500 enrolled1 locationNCT06075524
Recruiting
Phase 2

Esomeprazole and Radiation Induced Esophagitis

Locally Advanced Lung CarcinomaRadiation Esophagitis
Rush University Medical Center48 enrolled1 locationNCT06120803
Recruiting

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

NSCLC Stage IIILocally Advanced Lung Carcinoma
Jun Zhang, MD, PhD44 enrolled2 locationsNCT04680377